

## Mergers, Acquisitions, Cooperations, Licensing

August 17, 2016 - August 23, 2016

Activity*	When	Acquirer/ Buyer/ Driver/ Lincaser	Acquired/ Seller/ Participant/ Licensee	Short Activity Description/ Objective	Estimated Value
<b>C</b>	17-Aug-2016	Bavarian Nordic A/S	Bristol-Myers Squibb	Bavarian Nordic A/S announced the signature of a drug supply agreement with Bristol-Myers Squibb (BMS). Based on the agreement, BMS will supply OPDIVO® (nivolumab) to Bavarian Nordic for use in a clinical study. The trial, which will be sponsored by Bavarian Nordic, will enroll approximately 160 patients and will look to explore the benefit of combining CV301 with OPDIVO in patients with previously treated non-small cell lung cancer (NSCLC). OPDIVO is approved for treatment of patients with NSCLC in the second line setting, among other indications.	N/A
<b>C</b>	17-Aug-2016	Basilea Pharmaceutica Ltd.	Hikma Pharmaceuticals LLC	Basilea Pharmaceutica Ltd. announced that the company has extended its distribution and supply agreement for the Middle East and North Africa (MENA) region with Hikma Pharmaceuticals LLC (Hikma) to include the antifungal CRESEMBA® (isavuconazole) in addition to Zevtera® (ceftobiprole). In October 2015, Basilea signed an exclusive distribution and supply agreement with Hikma for Basilea's broad-spectrum hospital antibiotic Zevtera® for the MENA region. Under the terms of the amended agreement, Hikma has the exclusive right to register, distribute and market isavuconazole across the region.	N/A

\* A = Acquisition, M = Merger, C = Cooperation, L = In-, Outlicensing